These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10743281)

  • 1. Developing a national system for dealing with adverse events following immunization.
    Mehta U; Milstien JB; Duclos P; Folb PI
    Bull World Health Organ; 2000; 78(2):170-7. PubMed ID: 10743281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety monitoring in vaccine development and immunization.
    Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
    Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting of adverse events following immunization in Australia.
    Isaacs D; Lawrence G; Boyd I; Ronaldson K; McEwen J
    J Paediatr Child Health; 2005 Apr; 41(4):163-6. PubMed ID: 15813867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The monitoring of adverse events following immunization.
    Tatley M
    N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
    [No Abstract]   [Full Text] [Related]  

  • 8. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.
    ;
    Expert Rev Vaccines; 2009 Jun; 8(6):705-16. PubMed ID: 19485752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
    Miller M; Turner N
    N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
    [No Abstract]   [Full Text] [Related]  

  • 11. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.
    Gold MS; Gidudu J; Erlewyn-Lajeunesse M; Law B;
    Vaccine; 2010 Jun; 28(28):4487-98. PubMed ID: 20434547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
    Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
    Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring and assessing vaccine safety: a European perspective.
    Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J
    Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of standardized case definitions and guidelines for adverse events following immunization.
    Kohl KS; Gidudu J; Bonhoeffer J; Braun MM; Buettcher M; Chen RT; Drammeh B; Duclos P; Heijbel H; Heininger U; Hummelman E; Jefferson T; Keller-Stanislawski B; Loupi E; Marcy SM
    Vaccine; 2007 Aug; 25(31):5671-4. PubMed ID: 17400339
    [No Abstract]   [Full Text] [Related]  

  • 15. Monitoring vaccine safety during an influenza pandemic.
    Iskander J; Haber P; Herrera G
    Yale J Biol Med; 2005 Oct; 78(5):265-75. PubMed ID: 17132333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database.
    Letourneau M; Wells G; Walop W; Duclos P
    Vaccine; 2008 Feb; 26(9):1185-94. PubMed ID: 18243428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine adverse events in the new millennium: is there reason for concern?
    Ward BJ
    Bull World Health Organ; 2000; 78(2):205-15. PubMed ID: 10743286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The "Green Channel" of the Veneto region as a model for vaccine safety monitoring in Italy.
    Zanoni G; Ferro A; Valsecchi M; Tridente G
    Vaccine; 2005 Mar; 23(17-18):2354-8. PubMed ID: 15755627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse reactions to diphtheria-pertussis-tetanus vaccine in the Chilean Immunization Program].
    Abarca V K; Cerda L J; Ferreccio R C
    Rev Med Chil; 2009 Jan; 137(1):10-7. PubMed ID: 19399316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reporting vaccine-associated adverse events.
    Duclos P; Hockin J; Pless R; Lawlor B
    Can Fam Physician; 1997 Sep; 43():1551-6, 1559-60. PubMed ID: 9303234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.